This review will cover three new classes of potential therapies in treating MS, which are anti-CD40 ligand (CD40L) mAbs, chimeric antigen receptor (CAR) T cells, and Bruton’s tyrosine kinase inhibitors (BTKis) (Figure 1). The gene discussed is CD40LG; the disease is myeloid sarcoma.